AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33124144
Drug: CD4-driven planned
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CD4-driven planned treatment interruptions (PTI)
Trial: 36348453
Drug: Intensified TBM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified TBM regimen (oral high-dose rifampicin 35 mg/kg daily and linezolid 1200 mg daily then 600 mg daily for the first 8 weeks)
Trial: 36348453
Drug: Adjunctive aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive aspirin (200 mg daily)
Trial: 36348453
Drug: WHO standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO standard TB treatment
Trial: 33760026
Drug: 37% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37% phosphoric acid gel etchant for 15 seconds
Trial: 33504356
Drug: Online treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online treatment decision aid
Trial: 32565534
Drug: High-dose S-ketamine
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose S-ketamine
Trial: 32928863
Drug: Beta-alanine (BA)
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (BA) supplementation (3.2 g per day) during 8-10 week pulmonary rehabilitation program with NLPE training.
Trial: 32928863
Drug: Beta-alanine (BA)
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (BA) supplementation (3.2 g per day) during 8-10 week pulmonary rehabilitation program with NMES.
Trial: 32928863
Drug: Beta-alanine (BA)
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (BA) supplementation (3.2 g per day)
Trial: 34706665
Drug: GnRH-ant half-dose
RxNorm normalized name: wood ant preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH-ant half-dose (Group 1)
Trial: 34706665
Drug: GnRH-ant full-dose
RxNorm normalized name: wood ant preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH-ant full-dose (Group 2)
Trial: 33017045
Drug: Modified Kligman's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Kligman's triple combination (TC)
Trial: 34583744
Drug: Real-time PRO
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time PRO data captured with electronic mobile devices, weekly requests via an app to complete the PRO survey.
Trial: 33709142
Drug: Remdesivir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remdesivir (100 mg/day for 5 days)
Trial: 34752935
Drug: AT-001 (caficrestat)
RxNorm normalized name: AT-III
DrugBank: AT-001 (DB15121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-001 (caficrestat) 1500 mg BID for up to 14 days
Trial: 33479931
Drug: Home hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home hospital care (nurse and physician home visits, intravenous medications, remote monitoring, video communication, point‐of‐care testing)
Trial: 36329548
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and advice (treatment as usual, TAU) (n = 41)
Trial: 35103799
Drug: Brimonidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 2 mg/mL
Trial: 35103799
Drug: Brinzolamide 10
RxNorm normalized name: brinzolamide 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide 10 mg/mL
Trial: 35808843
Drug: Endothelial protocol
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelial protocol (Nicorandil, L-arginine, folate, Nebivolol, atorvastatin)
Trial: 33357007
Drug: Salbutamol (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (16 mg/day) during resistance training
Trial: 33443925
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TXA) 1300 mg per dose, three doses: 2 hours before surgery, and 6 and 12 hours after surgery.
Trial: 33443925
Drug: Oral ε‐aminocaproic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ε‐aminocaproic acid (EACA) 2000 mg per dose, three doses: 2 hours before surgery, and 6 and 12 hours after surgery.
Trial: 32519795
Drug: Tirzepatide (≥5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (≥5 mg for non-T2DM and ≥4.5 mg for T2DM)
Trial: 32519795
Drug: Tirzepatide (5/5/10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (5/5/10/10 or 5/5/10/15 mg) in T2DM participants
Trial: 32252004
Drug: rhIGF-I with
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF-I with oral estrogen-progesterone (EP)
Trial: 35588245
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day viloxazine extended-release
Trial: 33231117
Drug: Behavioral approaches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral approaches to aphasia treatment
Trial: 33231117
Drug: Pharmacotherapy options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy options
Trial: 33231117
Drug: Placebo-controlled behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-controlled behavioral treatments
Trial: 33576113
Drug: LTI-291 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTI-291 (3, 10, 30, and 90 mg single doses)
Trial: 33576113
Drug: LTI-291 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTI-291 (3, 10, 30, and 60 mg multiple doses)
Trial: 36074934
Drug: LED photobiomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED photobiomodulation therapy (PBMT) with red (630 nm) and infrared (850 nm) wavelengths
Trial: 36074934
Drug: Control (right
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (right side of abdomen, no treatment)
Trial: 33914197
Drug: Insulin (INS)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (INS) intervention
Trial: 34897211
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral placebo)
Trial: 34897211
Drug: Control (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (topical placebo)
Trial: 33334164
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behaviour therapy for insomnia (CBT-I)
Trial: 35482129
Drug: 1565-nm non-ablative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1565-nm non-ablative fractional laser combined with low-dose compound betamethasone topical application
Trial: 32537715
Drug: Fedratinib 500
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib 500 mg once-daily for 15 days
Trial: 32635661
Drug: Synbiotic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic preparation containing Lactobacillus and Bifidobacterium strains and fructooligosaccharides
Trial: 38794741
Drug: Synbiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic treatment
Trial: 36067791
Drug: Premarin Vaginal
RxNorm normalized name: Premarin Vaginal
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premarin Vaginal Cream (0.625 mg/g) once daily for 3 weeks
Trial: 36067791
Drug: Honglilai Vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honglilai Vaginal Cream
Trial: 36067791
Drug: Premarin Vaginal
RxNorm normalized name: Premarin Vaginal
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premarin Vaginal Cream
Trial: 32401633
Drug: FLAG (fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAG (fludarabine 30 mg/m2/dose on days 1-5; cytarabine 2000 mg/m2/dose on days 1-5; granulocyte-colony stimulating factor 5 mg/kg/dose, days 1-5 and day 15)
Trial: 34563397
Drug: PCV13 vaccine
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 vaccine
Trial: 35364620
Drug: Values-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Values-based cognitive behavioural therapy (V-CBT) delivered within 6 months post-injury, 10 sessions starting 1 week post-randomization (group A)
Trial: 35364620
Drug: Values-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Values-based cognitive behavioural therapy (V-CBT) delivered within 6 months post-injury, 10 sessions starting 3 months post-randomization (group B)
Trial: 33690227
Drug: Training data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training data group (drugs with known pharmacokinetic and physical parameters)
Trial: 32952016
Drug: RedSol (reducing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RedSol (reducing solution)
Trial: 32505857
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL retained cystoscopy fluid
Trial: 33866315
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (0.12 g)
Trial: 33772416
Drug: ADHD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADHD treatment
Trial: 35850141
Drug: Modified low
RxNorm normalized name: Minimally modified low density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified low dose protocol with tin filtering
Trial: 35850141
Drug: Conventional low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional low dose protocol without tin filtering
Trial: 34023839
Drug: Logistical regression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Logistical regression model adjusted for tooth mobility, bone or respiratory diseases, and consumption of anxiolytics and antidepressants
Trial: 35689905
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing counseling plus nicotine replacement therapy (NRT)
Trial: 33067258
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB) treatment with small-size balloon predilation (pBVR<0.8)
Trial: 33067258
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB) treatment with large-size balloon predilation (pBVR 0.8-1.0)
Trial: 32204222
Drug: Aspirin 80mg
RxNorm normalized name: Walgreens Infants' Non-Aspirin 80mg/0.8ml Drops (Grape)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 80mg plus pravastatin 20mg twice daily until 35 weeks gestation
Trial: 32204222
Drug: Aspirin 80mg
RxNorm normalized name: Walgreens Infants' Non-Aspirin 80mg/0.8ml Drops (Grape)
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 80mg
Trial: 35365190
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) applied once at the level of the lesion, five segments above/below, and on the plantar surface of both feet within the first 48 h after trauma (energy flux density: 0.1–0.19 mJ/mm2, frequency: 2–5 Hz)
Trial: 32460879
Drug: Ondansetron oral
RxNorm normalized name: Ondansetron Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron oral solution (six doses over 48 hours)
Trial: 32460879
Drug: Placebo (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (six doses over 48 hours)
Trial: 35695006
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Revacept
Trial: 35695006
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg Revacept
Trial: 35075525
Drug: Structured behavioral
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured behavioral support program with 7-weekly sessions
Trial: 32078469
Drug: Acetazolamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500 mg twice a day for 3 days)
Trial: 32926507
Drug: pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 200 mg every 3 weeks (35 cycles)
Trial: 32926507
Drug: chemotherapy (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy (four to six cycles)
Trial: 35130196
Drug: Dual injection
RxNorm normalized name: Dual Injection Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual injection
Trial: 34533816
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (MT) with taping
Trial: 34533816
Drug: Modified constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint‐induced movement therapy (mCIMT) alone
Trial: 34533816
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (MT) alone
Trial: 34098301
Drug: MOUD (Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOUD (Medication for Opioid Use Disorder)
Trial: 34098301
Drug: XR-NTX (Extended-Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-NTX (Extended-Release Naltrexone)
Trial: 34602484
Drug: B vitamin
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamin therapy (daily folic acid 0.8 mg, vitamin B12 0.5 mg, vitamin B6 20 mg)
Trial: 32290829
Drug: Oral dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dextrose
Trial: 36193322
Drug: Fu's subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu's subcutaneous needling therapy (FSN), treated once every other day for 5 consecutive treatments.
Trial: 36193322
Drug: Acupuncture, treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture, treated once a day for 10 consecutive treatments.
Trial: 32469835
Drug: Modified group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified group cognitive behavioral therapy (CBT), 8 weekly sessions of 60 minutes each
Trial: 35856326
Drug: Vapocoolant (cold)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapocoolant (cold) spray
Trial: 35856326
Drug: Injection without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection without anesthesia
Trial: 33570228
Drug: Phyllanthus emblica
RxNorm normalized name: PHYLLANTHUS EMBLICA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus emblica capsule (500 mg) twice daily for 12 weeks
Trial: 33570228
Drug: Phyllanthus emblica
RxNorm normalized name: PHYLLANTHUS EMBLICA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus emblica capsule (500 mg)
Trial: 33494637
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) including intra-arterial thrombolysis and mechanical thrombectomy (MT; ±IVT)
Trial: 33494637
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) after 2015
Trial: 34032043
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml compound betamethasone injection
Trial: 34032043
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml hyaluronic acid and 1 ml compound betamethasone injection
Trial: 34999335
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid, carotenoid and vitamin E supplementation (1 g fish oil, 430 mg DHA, 90 mg EPA, 22 mg carotenoids, 15 mg vitamin E)
Trial: 33388700
Drug: Treatment-as-usual plus
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual plus aerobic walking (TAW)
Trial: 35019055
Drug: Mindfulness-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based treatment (MBT)
Trial: 35723758
Drug: Pemetrexed +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed + treatment
Trial: 35723758
Drug: Pemetrexed -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed - treatment
Trial: 35723758
Drug: Pemetrexed +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed + treatment (among patients with at least four lines of prior treatment)
Trial: 35723758
Drug: Pemetrexed -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed - treatment (among patients with at least four lines of prior treatment)
Trial: 34601077
Drug: Hydrogen-rich water
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich water (HRW) 0.5 L per day (15 ppm of hydrogen)
Trial: 32886901
Drug: Upfront lanreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront lanreotide (120 mg)
Trial: 36224646
Drug: 2-channel PCA
RxNorm normalized name: CHANNEL CATFISH
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-channel PCA (16 μg/kg of fentanyl, 2 mg/kg of ketorolac, 12 mg of ondansetron)
Trial: 36224646
Drug: 1-channel PCA
RxNorm normalized name: PCA
DrugBank: Pidolic acid (DB03088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-channel PCA (16 μg/kg of fentanyl, normal saline in continuous channel)
Trial: 34590929
Drug: Myo 2
RxNorm normalized name: Nymyo 28 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo 2 g twice daily
Trial: 34590929
Drug: Met 850
RxNorm normalized name: Glucamet 850 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Met 850 mg twice daily
Trial: 33686715
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (listened to the lecture twice)
Trial: 36037999
Drug: Digoxin administration
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin administration in patients with heart failure (39 patients, 10.5%)
Trial: 36037999
Drug: Digoxin administration
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin administration in patients without heart failure (11 patients, 3.5%)
Trial: 35771851
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (singing lessons)
Trial: 35972301
Drug: CMO pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CMO pharmaceutical intervention model
Trial: 35972301
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (Control Group)
Trial: 33851765
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) using Gallium‐aluminum‐arsenide (GaAlAs) diode laser, applied immediately after surgery and for 15 days.
Trial: 33851765
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PBMT treatment).
Trial: 33518080
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg ALA/bird per day
Trial: 33518080
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg ALA/bird per day
Trial: 33518080
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ALA/bird per day
Trial: 33518080
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg ALA/bird per day
Trial: 33518080
Drug: 95 mg
RxNorm normalized name: aspirin 195 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95 mg ALA/bird per day
Trial: 33518080
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg ALA/bird per day
Trial: 33518080
Drug: 145 mg
RxNorm normalized name: levodopa 145 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 145 mg ALA/bird per day
Trial: 34388977
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of urine and breath samples
Trial: 33595409
Drug: All QY
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All QY treatments (250 and 500 ppm)
Trial: 32595060
Drug: GLASS Ⅰ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLASS Ⅰ, Ⅱ, and Ⅲ groups (Endovascular treatment)
Trial: 32595060
Drug: GLASS Ⅲ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLASS Ⅲ (Endovascular treatment)
Trial: 32595060
Drug: GLASS scoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLASS scoring system (Endovascular treatment)
Trial: 32595060
Drug: GLASS score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLASS score groups (Endovascular treatment)